Gapping up
In reaction to strong earnings/guidance:
- IRBT +9% (guidance)
Other news:
- ISEE +46.6% (announces "positive" 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura)
- VTVT +19.6% (Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association's Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients)
- BYSI +19.3% (announces positive topline interim results from Protective-2 phase 3 trial; meets primary endpoint)
- XERS +16.7% (announces "positive" results from the outpatient stage of a Phase 2 study of its developmental Gvoke Ready-to-Use (RTU) Micro glucagon in adults at risk of hypoglycemia during and after aerobic exercise)
- VXX +10% (rising with US futures trading lower)
- FLDM +8.4% (files for Emergency Use Authorization from FDA for saliva-based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19)
- CTLT +7.1% (will provide vial filling and packaging capacity to AstraZeneca PLC at Catalent's manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of the University of Oxford's adenovirus vector based COVID-19 vaccine candidate, AZD1222)
- WUBA +6.7% (following report that an investor group wants to bid over $55/ADS for the company)
- MRNA +4.5% (Israel close to deal with MRNA to supply experimental coronavirus vaccine)
- PRNB +3% (announces "positive" data from Phase 2 Part B BELIEVE-PV trial)
- CNCE +2.7% (reports new data analyses from Phase 2 trial of CTP-543 in alopecia areata)
- ZGNX +1.4% (files mixed securities shelf offering)
- CDXC +1.2% (files for $125 mln mixed securities shelf offering)
Analyst comments:
- SHOP +5.7% (upgraded to Overweight from Neutral at Piper Sandler)